AstraZeneca announces $50B of investment in U.S. by 2030

AstraZeneca (AZN) announces $50B of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar U.S. manufacturing facility that will produce drug substances for the company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5B announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. “The $50B investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland; State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts; Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; Continuous manufacturing expansion in Mount Vernon, Indiana; Specialty manufacturing expansion in Coppell, Texas; New sites to supply clinical trials. Our growing research and development investment in novel medicines. Collectively, these investments will help deliver AstraZeneca’s ambition of reaching $80B in Total Revenue by 2030, of which we expect 50% would be generated in the U.S.”